CA 23318/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
1980	7
1981	13
1982	16
1983	8
1984	15
1985	23
1986	12
1987	16
1988	4
1989	6
1990	12
1991	6
1992	15
1993	12
1994	8
1995	3
1996	7
1997	6
1998	8
1999	6
2000	3
2001	3
2002	3
2003	5
2004	5
2005	2
2006	1
2007	2
2008	1
2009	1
2010	1
2011	2
2012	1
2013	1
2015	1
2016	1
2022	0

1

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Schiller JH, et al. N Engl J Med. 2002 Jan 10;346(2):92-8. doi: 10.1056/NEJMoa011954. N Engl J Med. 2002. PMID: 11784875 Free article. Clinical Trial.

2

Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma.

Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, Loehrer PJ Sr. Lemma GL, et al. J Clin Oncol. 2011 May 20;29(15):2060-5. doi: 10.1200/JCO.2010.32.9607. Epub 2011 Apr 18. J Clin Oncol. 2011. PMID: 21502559 Free PMC article. Clinical Trial.

3

Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO Jr, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC. Dewys WD, et al. Am J Med. 1980 Oct;69(4):491-7. doi: 10.1016/s0149-2918(05)80001-3. Am J Med. 1980. PMID: 7424938

4

Thymoma: current medical and surgical management.

Kesler KA, Wright CD, Loehrer PJ Sr. Kesler KA, et al. Semin Neurol. 2004 Mar;24(1):63-73. doi: 10.1055/s-2004-829588. Semin Neurol. 2004. PMID: 15229793 Review.

5

Thymoma and thymic carcinoma: therapeutic approaches.

Kurup A, Loehrer PJ Sr. Kurup A, et al. Clin Lung Cancer. 2004 Jul;6(1):28-32. doi: 10.3816/CLC.2004.n.018. Clin Lung Cancer. 2004. PMID: 15310414 Review.

6

Current approaches to the treatment of thymoma.

Loehrer PJ Sr. Loehrer PJ Sr. Ann Med. 1999 Oct;31 Suppl 2:73-9. Ann Med. 1999. PMID: 10574160 Review.

7

Prognostic factors for survival in hepatocellular carcinoma.

Falkson G, Cnaan A, Schutt AJ, Ryan LM, Falkson HC. Falkson G, et al. Cancer Res. 1988 Dec 15;48(24 Pt 1):7314-8. Cancer Res. 1988. PMID: 2847868 Review.

8

Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer.

Falkson G, Gelman RS, Dreicer R, Tormey DC, Alberts AS, Coccia-Portugal MA, Rushing D, Bennett JM. Falkson G, et al. J Clin Oncol. 1989 Sep;7(9):1252-9. doi: 10.1200/JCO.1989.7.9.1252. J Clin Oncol. 1989. PMID: 2671284 Review.

9

Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP.

Lazar AA, Bonetti M, Cole BF, Yip WK, Gelber RD. Lazar AA, et al. Clin Trials. 2016 Apr;13(2):169-79. doi: 10.1177/1740774515609106. Epub 2015 Oct 22. Clin Trials. 2016. PMID: 26493094 Free PMC article. Clinical Trial.

10

Morphology and other prognostic factors of hepatocellular carcinoma.

Chedid A, Ryan LM, Dayal Y, Wolf BC, Falkson G. Chedid A, et al. Arch Pathol Lab Med. 1999 Jun;123(6):524-8. doi: 10.5858/1999-123-0524-MAOPFO. Arch Pathol Lab Med. 1999. PMID: 10383806 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results